VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 55 of Oncotarget features Figure 4, "(A) Regression tree diagram of the best combination of the identified autoantibody biomarkers. (B) Cumulative sensitivity and specificity of the 10 AAb biomarker panel. (C) ROC curve and AUC of the biomarker combination in cohort 1," by Zaenker, et al.
|
|
Table of Contents
Priority Research Papers
|
| The recent landscape of cancer research worldwide: a bibliometric and network analysis |
|
https://doi.org/10.18632/oncotarget.25730
|
| 30474-30484 |
Research Papers
|
| MicroRNA profiling and their pathways in South African individuals with prediabetes and newly diagnosed type 2 diabetes mellitus |
|
https://doi.org/10.18632/oncotarget.25271
|
| 30485-30498 |
|
| Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposurerelated lung adenocarcinoma patients |
|
https://doi.org/10.18632/oncotarget.25369
|
| 30499-30512 |
|
| APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer |
|
https://doi.org/10.18632/oncotarget.25495
|
| 30513-30526 |
|
| Preclinical nongenetic models of lung adenocarcinoma: a comparative survey |
|
https://doi.org/10.18632/oncotarget.25668
|
| 30527-30538 |
|
| A diagnostic autoantibody signature for primary cutaneous melanoma |
|
https://doi.org/10.18632/oncotarget.25669
|
| 30539-30551 |
|
| The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.25702
|
| 30552-30560 |
|
| Colorectal tumor prevention by the progestin medroxyprogesterone acetate is critically dependent on postmenopausal status |
|
https://doi.org/10.18632/oncotarget.25703
|
| 30561-30567 |
|
| A kmer based transcriptomics approach for antisense drug discovery targeting the Ewing’s family of tumors |
|
https://doi.org/10.18632/oncotarget.25736
|
| 30568-30586 |
|
| Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immunecheckpoint blockade |
|
https://doi.org/10.18632/oncotarget.25743
|
| 30587-30593 |
|
| Positive crosstalk between EGFR and the TFPAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer |
|
https://doi.org/10.18632/oncotarget.25748
|
| 30594-30609 |
|
| Serum Nglycome alterations in colorectal cancer associate with survival |
|
https://doi.org/10.18632/oncotarget.25753
|
| 30610-30623 |
|
| The nuclearcytoplasmic trafficking of a chromatinmodifying and remodelling protein KMT2C in osteosarcoma |
|
https://doi.org/10.18632/oncotarget.25755
|
| 30624-30634 |
|
| Extracellular ATP is a danger signal activating P2X7 receptor in a LPS mediated inflammation ARDS/ALI |
|
https://doi.org/10.18632/oncotarget.25761
|
| 30635-30648 |
|
| Clinical genetic testing outcome with multigene panel in Asian patients with multiple primary cancers |
|
https://doi.org/10.18632/oncotarget.25769
|
| 30649-30660 |
|
| SIRT1dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer |
|
https://doi.org/10.18632/oncotarget.25771
|
| 30661-30678 |
|
| Is water exchange superior to water immersion in detecting adenomas during colonoscopies Results from a Bayesian network metaanalysis |
|
https://doi.org/10.18632/oncotarget.25504
|
| 30679-30693 |
Clinical Research Papers
|
| Dry eye syndrome and the subsequent risk of chronic fatigue syndrome—a prospective populationbased study in Taiwan |
|
https://doi.org/10.18632/oncotarget.25544
|
| 30694-30703 |
Reviews
|
| Programmed cell death: the battlefield between the host and alphaherpesviruses and a potential avenue for cancer treatment |
|
https://doi.org/10.18632/oncotarget.25694
|
| 30704-30719 |
Corrections
|
| Correction: Upregulation of microRNA135a3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis |
|
https://doi.org/10.18632/oncotarget.25777
|
| 30720-30720 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
